Mercaptamine
ATC S01XA21 · 5 markets · 26 records
GB 10 records · 5 shown of 5
- 150 mgcapsuleCystagon
- 75 mgcapsule · delayed-releaseProcysbi 25mg gastro-resistant capsules
- 50 mgcapsuleCystagon
- 25 mgcapsule · delayed-releaseProcysbi 25mg gastro-resistant capsules
- 3.8 mgliquidCystadrops 3.8mg/ml eye drops
5 records · 1 manufacturers 5 registros · 1 fabricantes 5 个记录 · 1 个厂家 5 個記錄 · 1 個廠商
and 1 more (1 manufacturers) y 1 más (1 fabricantes) 还有 1 个(1 个厂家) 還有 1 個(1 個廠商)
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
FR 5 records · 5 shown of 5
- 3.8 mgliquidCYSTADROPS 3,8 mg/mL, collyre en solution
- 221.1 mgtablet · delayed-releasePROCYSBI 25 mg, gélule gastro-résistante
- 73.7 mgtablet · delayed-releasePROCYSBI 25 mg, gélule gastro-résistante
- 441.72 mgcapsuleCYSTAGON 150 mg, gélule
- 147.24 mgcapsuleCYSTAGON 150 mg, gélule
ES 4 records · 4 shown of 4
EU 4 records · 0 shown of 0
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
4 records · 0 manufacturers 4 registros · 0 fabricantes 4 个记录 · 0 个厂家 4 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
AU 2 records · 1 shown of 1
- 3.8 mg/mLliquidCYSTADROPS - mercaptamine (cysteamine) (as hydrochloride) 3.8 mg/mL eye drops solution vial
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包
| Strength / form / release | GB | AU | ES | EU | FR |
|---|---|---|---|---|---|
| 150 mg capsule | Cystagon | Cystagon | |||
| 75 mg capsule · delayed-release | Procysbi 25mg gastro-resistant capsules | PROCYSBI | |||
| 50 mg capsule | Cystagon | Cystagon | |||
| 25 mg capsule · delayed-release | Procysbi 25mg gastro-resistant capsules | PROCYSBI | |||
| 3.8 mg liquid | Cystadrops 3.8mg/ml eye drops | CYSTADROPS 3,8 mg/mL, collyre en solution | |||
| 221.1 mg tablet · delayed-release | PROCYSBI 25 mg, gélule gastro-résistante | ||||
| 73.7 mg tablet · delayed-release | PROCYSBI 25 mg, gélule gastro-résistante | ||||
| 441.72 mg capsule | CYSTAGON 150 mg, gélule | ||||
| 147.24 mg capsule | CYSTAGON 150 mg, gélule | ||||
| 3.8 mg/mL liquid | CYSTADROPS - mercaptamine (cysteamine) (as hydrochloride) 3.8 mg/mL eye drops solution vial | ||||
unknown | CYSTADROPS | CYSTADROPS Cystagon Dropcys+1PROCYSBI | |||
liquid | Manufacturer: Special Order ×4 Cystaran 0.44% eye drops |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
2 more strength/form rows are recorded only in AU · EU and are not shown in this table. Hay 2 filas de concentración/forma registradas solo en AU · EU que no se muestran en esta tabla. 另有 2 个规格/剂型仅在 AU · EU 有记录(未在本表显示)。 另有 2 個規格/劑型僅在 AU · EU 有記錄(未在本表顯示)。
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Australia ARTG data has no registration-status column, so status is shown as unknown; being on the register does not mean currently marketed.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.